Ovarian Cancer

Editorial Chairs: Professor CN Hudson Editor of the First Edition, extremely high profile internationally, Professor of Obstetrics & Gynaecology, St Bartholomew's Hospital, London. Professor Ian Jacobs Original Editor and also a member of the Helene Harris Memorial Trust. In 1996 he was appointed to his current post which involves both clinical responsibilities for gynaecological oncology and direction of the Gynaecological Cancer Research Unit at St Bartholomew's and The Royal London Hospitals Medical School. In addition to directing the molecular and clinical studies organised through this unit, Ian Jacobs is co-ordinator of national collaborative studies of interval debulking surgery in ovarian cancer (MRC) and of screening for familial ovarian cancer (UKCCCR). Editorial Board Dr John Shepherd Editor of the First Edition, extremely high profile internationally, based at St Bartholomew's Hospital, London.where he has established the largest (and arguably the most prestigious) g

Introduction; PART 1: AETIOLOGY; 1. Epidemiology of sporadic ovarian cancer; 2. Associations between infertility, its treatment and ovarian cancer risk; 3. The molecular basis of sporadic ovarian cancer; 4. Overview of the aetiology of familial ovarian cancer; 5. The prevalence of mutations in BRCA1 and BRCA2; 6. The penetrance of BRCA1/2 mutations; 7. Founder mutations of BRCA1/2; 8. Clinical implications of genetic testing; PART 2: NATURAL HISTORY AND PATHOLOGY; 9. Pathology of epithelial ovarian cancer; 10. Pathology of borderline ovarian malignancy; 11. Primary non-epithelial ovarian cancers; 12. Metastases in the ovary; 13. Genetic analysis of putative precursors of ovarian cancer; 14. Molecular pathogenesis of borderline and invasive ovarian tumours; PART 3: TUMOR BIOLOGY; 15. The application of novel technology to the study of ovarian cancer; 16. The biology of the ovarian surface epithelium; 17. The tumour microenvironment of epithelial ovarian cancer; 18. ARHI (NOEY2), a novel imprinted tumour suppressor gene in ovarian cancer; 19. Regulation of angiogenesis in ovarian cancer: role of p53, vascular endothelial growth factor, and hypoxia; 20. Role of Fas/FasL in the control of human ovary growth and progression; PART 4: PREVENTION AND SCREENING; 21. The surgical prevention of ovarian cancer; 22. Chemoprevention of ovarian cancer; 23. Biologic effect of progestins on ovarian epithelium: cancer prevention through apoptosis?; 24. The current status of screening for ovarian cancer; 25. Optimising the use of ultrasonography in ovarian cancer screening; 26. Doppler ultrasound derived indices in screening and diagnosis of ovarian cancer; 27. Differentiating the risk of ovarian cancer calculation from CA125 velocity: a new concept for optimizing CA125 screening for ovarian cancer; 28. Socioeconomics of ovarian cancer screening; 29. The management of familial ovarian cancer; PART 5: DIAGNOSTIC AND PROGNOSTIC TECHNIQUES; 30. Clinical diagnosis including para-neoplastic syndromes; 31. Serum tumour markers in the clinical management of ovarian cancer; 32. Three-dimensional ultrasound and color-flow studies; 33. CT and MRI of ovarian cancer; 34. Radionuclide imaging; 35. Telomerase in ovarian cancer: possible diagnostic test and therapeutic target; 36. Detection of circulating tumour cells in the peripheral blood and bone marrow of patients with ovarian cancer; PART 6: SURGICAL MANAGEMENT OF OVARIAN CANCER; 37. Overview of primary surgery for ovarian cancer; 38. Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study; 39. The role of surgery in relapse and palliation of ovarian cancer; 40. The role of minimal access surgery in ovarian cancer; 41. The organization of care; 42. Patterns of care in ovarian cancer; PART 7: ADJUVANT AND PALLIATIVE THERAPY FOR OVARIAN CANCER; 43. Current chemotherapy options in ovarian cancer; 44. Chemotherapy for epithelial cancer of the ovary; 45. Neoadjuvant chemotherapy in advanced ovarian carcinoma: present and future prospects; 46. Randomized trials in epithelial ovarian cancer: the Gynaecological Oncology Group studies; PART 8: NOVEL THERAPIES: THE FUTURE; 47. Angiogenesis in epithelial ovarian cancer: an important biological event and therapeutic target; 48. Delivery of genes to ovarian cancer using targeted vectors based on self-assembling polymers; 49. Corporate drug discovery strategies; 50. DNA mismatch repair and drug resistance; 51. Gene therapy and immunomodulation; 52. Preclinical and phase 1 clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer; 53. Paclitaxel resistance in human ovarian cancer: role of apoptosis-related proteins; 54. Trials of p53 gene therapy: rationale and preliminary studies; 55. Phosphatidylinostol 3'-kinase as a target in ovarian cancer: from genomics to therapeutics